Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cetuximab biosimilar by Dragonboat Biopharmaceutical (Shanghai) for Penile Cancer: Likelihood of Approval
Cetuximab biosimilar is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Penile Cancer. According to...
Cetuximab biosimilar by Dragonboat Biopharmaceutical (Shanghai) for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Cetuximab biosimilar is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Head And Neck Squamous...
Cetuximab biosimilar by Dragonboat Biopharmaceutical (Shanghai) for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Cetuximab biosimilar is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Esophageal Squamous Cell Carcinoma...
Cetuximab biosimilar by Alkem Laboratories for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Cetuximab biosimilar is under clinical development by Alkem Laboratories and currently in Phase III for Oral Cavity (Mouth) Cancer. According...
Cetuximab biosimilar by Alkem Laboratories for Lip Cancer: Likelihood of Approval
Cetuximab biosimilar is under clinical development by Alkem Laboratories and currently in Phase III for Lip Cancer. According to GlobalData,...
Cetuximab biosimilar by Alkem Laboratories for Pharyngeal Neoplasm: Likelihood of Approval
Cetuximab biosimilar is under clinical development by Alkem Laboratories and currently in Phase III for Pharyngeal Neoplasm. According to GlobalData,...
Cetuximab biosimilar by Alkem Laboratories for Locally Recurrent Or Locoregional Solid Malignancies: Likelihood of Approval
Cetuximab biosimilar is under clinical development by Alkem Laboratories and currently in Phase III for Locally Recurrent Or Locoregional Solid...